Other research analysts have also recently issued reports about the company. BidaskClub upgraded Aurinia Pharmaceuticals from a sell rating to a hold rating in a research note on Saturday, November 30th. Bloom Burton reaffirmed a buy rating on shares of Aurinia Pharmaceuticals in a research note on Wednesday, October 2nd. HC Wainwright set a $25.00 price objective on Aurinia Pharmaceuticals and gave the company a buy rating in a report on Friday, November 1st. Zacks Investment Research raised Aurinia Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, November 28th. Finally, Oppenheimer raised their target price on Aurinia Pharmaceuticals from $14.00 to $22.00 in a report on Thursday. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Aurinia Pharmaceuticals has an average rating of Buy and an average target price of $18.46.
Aurinia Pharmaceuticals stock opened at $15.44 on Thursday. The company’s 50 day simple moving average is $6.08 and its 200-day simple moving average is $6.03. Aurinia Pharmaceuticals has a 1 year low of $3.52 and a 1 year high of $17.48. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of -20.32 and a beta of 1.27.
Institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC boosted its position in Aurinia Pharmaceuticals by 630.1% in the 3rd quarter. Tower Research Capital LLC TRC now owns 8,382 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 7,234 shares during the period. Benjamin F. Edwards & Company Inc. raised its position in Aurinia Pharmaceuticals by 42.9% in the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 10,000 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 3,000 shares in the last quarter. Toronto Dominion Bank raised its position in Aurinia Pharmaceuticals by 26.3% in the 2nd quarter. Toronto Dominion Bank now owns 12,355 shares of the biotechnology company’s stock valued at $81,000 after purchasing an additional 2,575 shares in the last quarter. UBS Asset Management Americas Inc. purchased a new position in shares of Aurinia Pharmaceuticals in the 2nd quarter valued at about $88,000. Finally, A.R.T. Advisors LLC boosted its stake in shares of Aurinia Pharmaceuticals by 44.9% in the 2nd quarter. A.R.T. Advisors LLC now owns 18,395 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 5,700 shares during the period. Institutional investors own 27.00% of the company’s stock.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Featured Article: Buy Rating
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.